Enters Human

• Oxford University has launched Phase 1 human trials for a new Ebola vaccine targeting the Bundibugyo strain, supported by CEPI. • The Serum Institute is producing over 620,000 doses, with the trial beginning just 57 days after the WHO declared the outbreak a Public Health Emergency of International Concern. • This rapid development marks one of the fastest responses to an emerging infectious disease, aiming to curb the spread of the rare strain.

• UK scientists from the University of Oxford and biotechnology firm Basecamp Research have launched human trials for the world's first AI-designed vaccine. • The vaccine targets Crimean-Congo haemorrhagic fever (CCHF), a potentially fatal viral disease primarily transmitted to humans via tick bites. • This milestone represents a significant shift in medical research, demonstrating how artificial intelligence can accelerate the design and development of complex drugs.